The much-anticipated Senores Pharmaceuticals IPO allotment has generated a buzz among investors. With an overwhelming response, the IPO showcased robust demand across all investor categories. Here’s everything you need to know about the allotment status, listing details, and what it means for investors.
Highlights of Senores Pharmaceuticals IPO
- Issue Size: ₹582.11 crore
- Fresh Issue: ₹500 crore
- Offer-for-Sale: ₹82.11 crore
- Price Band: ₹372-₹391 per share
- Subscription Details:
- Overall: 93.69 times
- Qualified Institutional Buyers (QIBs): 94.66 times
- Non-Institutional Investors (NIIs): 96.30 times
- Retail Investors: 90.46 times
- Listing Date: December 30, 2024
Financial Performance of Senores Pharmaceuticals
The company has exhibited significant growth over the past few years. Below is a summary of its financial trajectory:
| Financial Year | Revenue (₹ crore) | Net Profit (₹ crore) |
|---|---|---|
| FY22 | 14.17 | 0.99 |
| FY23 | 35.34 | 8.44 |
| FY24 | 214.52 | 32.71 |
| Q1 FY25 | 181.02 | 23.94 |
The company’s impressive growth trajectory is attributed to its focus on regulated markets like the US, Canada, and the UK, along with its presence in emerging markets.
How to Check Senores Pharmaceuticals IPO Allotment Status
Investors can check the allotment status through the NSE, BSE, or the registrar Link Intime India. Follow these steps:
On NSE Website:
- Visit the NSE IPO allotment page.
- Log in or register as a new user.
- Select “Senores Pharmaceuticals Ltd” from the dropdown.
- Enter your application number and PAN.
- Click “Submit” to view the status.
On BSE Website:
- Visit the BSE allotment page.
- Choose “Equity” as the issue type.
- Select “Senores Pharmaceuticals Ltd” from the dropdown.
- Enter your application number and PAN.
- Verify using CAPTCHA and click “Search.”
On Link Intime India Portal:
- Visit the Link Intime IPO page.
- Select “Senores Pharmaceuticals Ltd.”
- Enter your details (Application No., DP ID, or PAN).
- Choose the application type (ASBA or non-ASBA).
- Complete the CAPTCHA and click “Submit.”
Grey Market Premium (GMP) Insights
The IPO has witnessed a steady grey market premium (GMP) of ₹240, indicating a potential listing gain of up to 60%. This reflects strong investor confidence despite market volatility.
Key Reasons for Investor Interest
- Strong Financial Growth: Revenue surged from ₹14.17 crore in FY22 to ₹214.52 crore in FY24.
- Global Presence: Operations in regulated markets like the US, UK, and Canada.
- Diverse Portfolio: Over 55 products in therapeutic areas like antibiotics and antifungal treatments.
- Utilization of Funds: Proceeds to be used for manufacturing facilities, working capital, debt repayment, and corporate purposes.
Conclusion
The Senores Pharmaceuticals IPO has proven to be a success story, with investors eagerly awaiting its market debut. For those who missed the allotment, the stock’s listing on December 30, 2024, offers another opportunity to participate in its journey.
Disclaimer
This article is for informational purposes only and should not be construed as investment advice. Always consult a certified financial advisor before making investment decisions.
Stay tuned to FinGuys.in for more financial insights and updates!